stemcells inc (STEM) Key Developments
StemCells, Inc. Appoints Alan Trounson to Board of Directors
Jul 7 14
StemCells Inc. announced the appointment of Alan Trounson, Ph.D. to its Board of Directors. Dr. Trounson most recently served as President of The California Institute of Regenerative Medicine (CIRM).
StemCells Inc. - Special Call
Jun 19 14
To discuss the interim results from the Phase I/II clinical trial of HuCNS-SC cells in dry AMD
StemCells, Inc. Interim Results Show Improvement in Visual Function and Slowing of Disease Progression in Phase I/II Dry Amd Trial
Jun 19 14
StemCells Inc. reported positive interim results from its Phase I/II clinical trial of the Company's proprietary HuCNS-SC(R) human neural stem cell platform in dry age-related macular degeneration at the 12th annual meeting of the International Society for Stem Cell Research (ISSCR) in Vancouver, Canada. Interim trial results show a 65% reduction in the rate of geographic atrophy (GA) in the study eye when compared to the expected natural history of the disease as well as a 70% reduction in the rate of GA when compared to the control eye. GA is the progressive loss of two important retinal tissue layers, the photoreceptors and the retinal pigmented epithelium. This degeneration is the cause of vision loss in dry AMD. Interim results also indicate improvements in visual function, as measured by the ability to distinguish shades of light versus dark, also referred to as "contrast sensitivity." Contrast sensitivity was improved in four of the seven patients and remained stable in the other three patients. The interim analysis is based on a minimum follow up of at least 6 months and demonstrates a favorable safety profile for administration of the HuCNS-SC cells into the sub-retinal space of the study eye.
StemCells Inc. Presents at BIO International Convention, Jun-25-2014 04:15 PM
Jun 17 14
StemCells Inc. Presents at BIO International Convention, Jun-25-2014 04:15 PM. Venue: San Diego Convention Center, San Diego, California, United States. Speakers: Martin M. McGlynn, Chief Executive Officer, President, Director, Member of Strategic Transactions Committee, Chief Executive Officer of StemCells California Inc and President of StemCells California Inc.
StemCells Inc. Strengthens Senior Executive Team
Jun 17 14
StemCells Inc. announced one promotion and three new appointments to the company's executive team. Stephen Huhn, M.D., F.A.C.S., F.A.A.P. has been promoted to the newly created position of vice president, CNS clinical research and chief medical officer. Joel Naor, M.D., M.B.A., M.Sc., has joined StemCells Inc. as vice president, clinical development, ophthalmology, and will report to Dr. Stephen Huhn; Naymisha Patel has joined StemCells Inc. as vice president, quality systems; and Mohammad A. El-Kalay, Ph.D. has joined StemCells Inc. as vice president, process development. Dr. Huhn, Ms. Patel and Dr. El-Kalay will report to Martin McGlynn president and chief executive officer of StemCells Inc. As chief medical officer, Dr. Huhn will continue to oversee all aspects of the company's clinical activities. Dr. Naor brings more than 14 years of experience drug development for retinal conditions, and will be responsible for the development of cell-based products for retinal diseases, initially from the company's proprietary HuCNS-SC(R) platform technology. Naymisha Patel will be responsible for driving the corporate quality agenda and implementing Quality Management Systems appropriate for planned clinical and manufacturing growth. Mohammad A. El-Kalay, Ph.D., will be responsible for developing scalable and efficient manufacturing processes and assays to meet the increasing clinical and development demand for products.